Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 701–800 of 1,010
Using DNA sequencing data to quantify T cell fraction and therapy response
Bentham, R. B., Litchfield, K., Watkins, T. B. K., Lim, E. L., Rosenthal, R., Martínez‐Ruiz, C., Hiley, C. T., Bakir, M. A., Salgado, R., Moore, D. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03894-5 · Cited by 68
Elcheva, I. A., Gowda, C. P., Bogush, D., Gornostaeva, S., Fakhardo, A., Sheth, N., Kokolus, K. M., Sharma, A., Dovat, S., Uzun, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224516 · Cited by 66
Melanoma Immunotherapy: Next-Generation Biomarkers
Hogan, S. A., Levesque, M. P., & Cheng, P. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00178 · Cited by 74
“performed WES on 110 patients and RNAseq on 40 patients treated with anti-CTLA-4 (32).”
BackgroundMorse, C. B., Toukatly, M. N., Kilgore, M., Agnew, K. J., Bernards, S. S., Norquist, B. M., Pennington, K. P., Garcia, R. L., Liao, J. B., & Swisher, E. M. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.02.011 · Cited by 68
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 85
Kang, H., Pettinga, D., Schubert, A. D., Ladenson, P. W., Ball, D. W., Chung, J., Schrock, A. B., Madison, R. W., Frampton, G. M., Stephens, P. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0334 · Cited by 67
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
Yu, Y.-R., & Ho, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13293 · Cited by 69
Sugawara, K., Iwai, M., Ito, H., Tanaka, M., Seto, Y., & Todo, T. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.004 · Cited by 72
“Further novel therapies are needed that can facilitate the priming of the immune system with a tumor neoantigen, lead effector T cell trafficking, and reverse the immunosuppressive tumor microenvironment (TME).(5,6)”
BackgroundCancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
“ICB effectiveness can be affected by the degree of CD8+ T cell infiltration (50), mutation or neo-antigen load (23), PD-L1 level (51), antigen presentation defects (52), interferon signaling (53), mismatch repair defIciency (54), tumor aneuploidy (55) and intestinal microbiota (56).”
BackgroundDesbois, M., Vu, P. L., Coutzac, C., Marcheteau, E., Béal, C., Terme, M., Gey, A., Morisseau, S., Teppaz, G., Boselli, L., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600019 · Cited by 66
The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction
Creech, A. L., Ting, Y. S., Goulding, S. P., Sauld, J. F. K., Barthelme, D., Rooney, M. S., Addona, T. A., & Abelin, J. G. (2018) · PROTEOMICS · doi:10.1002/pmic.201700259 · Cited by 65
Qu, Y., Wen, J., Thomas, G. D., Yang, W., Prior, W., He, W., Sundar, P. D., Wang, X., Potluri, S., & Salek‐Ardakani, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107873 · Cited by 73
Criscuolo, D., Morra, F., Giannella, R., Visconti, R., Cerrato, A., & Celetti, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1089-z · Cited by 64
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., & Cortés, J. (2020) · BioDrugs · doi:10.1007/s40259-020-00436-9 · Cited by 69
Wang, W., Yuan, T., Ma, L., Zhu, Y., Bao, J., Zhao, X., Zhao, Y., Zong, Y., Zhang, Y., Yang, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105810 · Cited by 78
SHP-1: the next checkpoint target for cancer immunotherapy?
Watson, H. A., Wehenkel, S. C., Matthews, R. J., & Ager, A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150251 · Cited by 70
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Kiyotani, K., Chan, T., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13498 · Cited by 64
“A more recent study also found the predictive power for neoantigen load in anti-CTLA-4-treated melanoma patients.(15) More importantly, mismatch-repair proficiency was associated with clinical response; it was observed that patients who”
BackgroundStrategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies
Smith, E. A., & Hodges, H. C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.05.009 · Cited by 64
Lu, Y.-C., Jia, L., Zheng, Z., Tran, E., Robbins, P. F., & Rosenberg, S. A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0299 · Cited by 64
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4118 · Cited by 64
“Given these differences, the lack of similarity between the transcriptomic response we observed and the classic transcriptomic response to ipilimumab in melanoma (27), and the transcriptomic separation between responders and nonresponders and between pre- and ontreatment biopsies, we assert that these responses are th…”
Backgroundvan den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Pestinger, V., Smith, M. R., Sillo, T., Findlay, J. M., Laes, J., Martin, G., Middleton, G., Taniere, P., & Beggs, A. D. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00462-x · Cited by 63
m 6 A modification patterns and tumor immune landscape in clear cell renal carcinoma
Zhong, J., Liu, Z., Cai, C., Duan, X., Deng, T., & Zeng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001646 · Cited by 83
Liu, R., Yang, F., Yin, J., Liu, Y., Zhang, W., & Zhou, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685370 · Cited by 77
“In a recent study, Kagamu et al. (43) showed that a heightened frequency of CD62LlowCD4+ T cells in NSCLC patients’ peripheral blood at baseline was predictive of favorable PFS following anti-PD-1 treatment.”
BackgroundInfluentialChu, Y., Qian, L., Ke, Y., Feng, X., Chen, X., Liu, F., Yu, L., Zhang, L., Tao, Y., Xu, R. C., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01397-7 · Cited by 70
The Black Hole: CAR T Cell Therapy in AML
Atilla, E., & Benabdellah, K. (2023) · Cancers · doi:10.3390/cancers15102713 · Cited by 68
Mutanome directed cancer immunotherapy
Vormehr, M., Diken, M., Boegel, S., Kreiter, S., Türeci, Ÿ., & Şahin, U. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.001 · Cited by 70
Panda, A., Betigeri, A. M., Subramanian, K., Ross, J. S., Pavlick, D. C., Ali, S. M., Markowski, P. A., Silk, A. W., Kaufman, H. L., Lattime, E. C., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00146 · Cited by 70
“Using RNA-seq and whole exome sequencing (WXS) data for all solid cancers in The Cancer Genome Atlas (TCGA), we ask 3 questions: (1) Is there a mutational burden threshold above which there is a signature of immune activation and immunecheckpoint pathway up-regulation in some cancers? (2) Can this threshold be identif…”
MethodGermline Features Associated with Immune Infiltration in Solid Tumors
Shahamatdar, S., He, M. X., Reyna, M. A., Gusev, A., AlDubayan, S. H., Allen, E. M. V., & Ramachandran, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.039 · Cited by 67
Xie, F., Zhang, J. J., Wang, J., Reuben, A., Xu, W., Yi, X., Varn, F. S., Ye, Y., Cheng, J., Yu, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1744 · Cited by 66
“However, substantial discrepancies have been observed between different cancer types and even within the same cancer types (16, 19, 20) for each one of these genomic features individually as predictive biomarkers re fl ecting the profound heterogeneous nature of various types of cancers.”
BackgroundMethodSuch, L., Zhao, F., Liu, D. H., Thier, B., Le‐Trilling, V. T. K., Sucker, A., Coch, C., Pieper, N., Howe, S., Bhat, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131572 · Cited by 68
Self-citationSong, W.-M., Agrawal, P., Von Itter, R., Fontanals-Cirera, B., Wang, M., Zhou, X., Mahal, L. K., Hernando, E., & Zhang, B. (2021) · Nature Communications · doi:10.1038/s41467-021-21457-0 · Cited by 62
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
Li, S., Simoni, Y., Zhuang, S., Gabel, A. M., Ma, S., Chee, J., Islas, L., Cessna, A., Creaney, J., Bradley, R. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025570118 · Cited by 62
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 65
Ahn, R., Sabourin, V., Bolt, A. M., Hébert, S., Totten, S., Jay, N. D., Festa, M. C., Young, Y. K., Im, Y. K., Pawson, T. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14638 · Cited by 68
Characterizing neoantigens for personalized cancer immunotherapy
Capietto, A.-H., Jhunjhunwala, S., & Delamarre, L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.007 · Cited by 65
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 73
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 61
RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery
Pennock, N. D., Jindal, S., Horton, W. R., Sun, D., Narasimhan, J., Carbone, L., Fei, S. S., Searles, R. P., Harrington, C. A., Burchard, J., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0643-z · Cited by 65
Mutation load estimation model as a predictor of the response to cancer immunotherapy
Lyu, G.-Y., Yeh, Y.-H., Yeh, Y., & Wang, Y. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0051-x · Cited by 62
“In addition to lung adenocarcinoma, previous studies showed that the tumor mutation load is associated with the degree of clinical benefit of immunotherapy in melanomas.(17,18) Therefore, we investigated whether the mutation load estimation model developed using lung adenocarcinoma data can also be employed to estimat…”
BackgroundSena, L. A., Fountain, J., Velho, P. I., Lim, S. J., Wang, H., Nizialek, E. A., Rathi, N., Nussenzveig, R. H., Maughan, B. L., Vélez, M. G., et al. (2020) · The Oncologist · doi:10.1002/onco.13601 · Cited by 65
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Pan, D., Hu, A. Y., Antonia, S. J., & Li, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.021 · Cited by 68
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 66
Lu, Y., Zheng, Z., Lowery, F. J., Gartner, J. J., Prickett, T. D., Robbins, P. F., & Rosenberg, S. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002595 · Cited by 69
Kovacs, S., & Győrffy, B. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03409-4 · Cited by 66
“Granzyme a (GZMA), perforin 1 (PRF1), CTLA-4, and PD-L2 overexpression, and signatures connected to cytolytic activity, immune infiltration, neoantigen load, and overall mutational load had a significant correlation with clinical benefit in patients treated with ipilimumab [64].”
BackgroundDefining and using immune archetypes to classify and treat cancer
Combes, A. J., Samad, B., & Krummel, M. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00578-2 · Cited by 67
Subramanian, A., Nemat‐Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradić, M., Torres, I. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00743-y · Cited by 72
“Clinical annotations and normalized count data for patients with metastatic melanoma treated with anti-PD-1 antibodies 41,67 or anti-CTLA4 antibodies 68,69 were downloaded from the supplementary material of the published manuscripts.”
Zhang, P., Zhang, M., Liu, J.-L., Zhou, Z., Zhang, L., Luo, P., & Zhang, Z. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012069 · Cited by 66
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 82
Plant, A., Koyama, S., Sinai, C. E., Solomon, I. H., Griffin, G. K., Ligon, K. L., Bandopadhayay, P., Betensky, R. A., Emerson, R., Dranoff, G., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2737-9 · Cited by 63
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 69
“Whole-exome sequencing has revealed the mutational load of tumors as a major predictor of ICB response.[94-98] Underlying these observations is the hypothesis that somatic mutations lead to tumor-specific neoantigens that can overcome self-tolerance (Fig.”
Kim, K., Kim, H. S., Kim, J. Y., Jung, H., Sun, J., Ahn, J. S., Ahn, M., Park, K., Lee, S., & Choi, J. K. (2020) · Nature Communications · doi:10.1038/s41467-020-14562-z · Cited by 67
Ballotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 67
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Chen, B., Hu, J., Hu, X., Chen, H., Bao, R., Zhou, Y., Ye, Y., Zhan, M., Cai, W., Li, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29754-y · Cited by 64
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 67
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
Liu, X., Cen, X., Wu, R., Chen, Z., Xie, Y., Wang, F., Shan, B., Zeng, L., Zhou, J., Xie, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39920-5 · Cited by 70
Ye, Z., Dong, H., Li, Y., Ma, T., Huang, H., Leong, H. S., Eckel-Passow, J., Kocher, J.-P. A., Liang, H., & Wang, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3008 · Cited by 59
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 64
Park, W., Kwon, D., Saravia, D., Desai, A. J., Vargas, F., Dinali, M. E., Warsch, J. R. L., Elias, R. M., Chae, Y. K., Kim, D. W., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.007 · Cited by 62
PRKDC : new biomarker and drug target for checkpoint blockade immunotherapy
Tan, K. T., Yeh, C., Chang, Y., Cheng, J.-H., Fang, W., Yeh, Y., Wang, Y., Hsu, D. S., Wu, C., Lai, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000485 · Cited by 71
Self-citationUbiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Traets, J. J. H., Altimari, D. M. D., Vliet, A. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29442-x · Cited by 63
Bedognetti, D., Roelands, J. P., Decock, J. V., Wang, E., & Hendrickx, W. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170142 · Cited by 61
Emerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 61
Krieger, T., Pearson, I. V., Bell, J. A., Doherty, J. P., & Robbins, P. B. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-0927-9 · Cited by 63
Chen, Y., Wang, Y., Luo, H., Meng, X., Zhu, W., Wang, D., Zeng, H., & Zhang, H. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00173-3 · Cited by 71
SMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
Liu, L., Ahmed, T., Petty, W. J., Grant, S. C., Ruiz, J., Lycan, T. W., Topaloĝlu, Ü., Chou, P., Miller, L. D., Hawkins, G. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12831 · Cited by 59
“undergoing evaluation as a predictive biomarker in many tumor types [7, 12-14].”
BackgroundPagadala, M. S., Sears, T. J., Wu, V. H., Pérez‐Guijarro, E., Kim, H., Castro, A., Talwar, J. V., González-Colín, C., Cao, S., Schmiedel, B. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38271-5 · Cited by 66
“Differential gene expression analysis between responders and non-responders from cohorts Riaz et al. 60 , Hugo et al. 2016, Miao et al. 161 , and Van Allen et al. 58 was performed using the DESeq2 143 package in R. Cohort was included as a covariate when calculating top differentially expressed…”
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Use of LDH and Autoimmune Side Effects to Predict Response to Ipilimumab Treatment
Dick, J., Lang, N., Slynko, A., Kopp-Schneider, A., Schulz, C., Dimitrakopoulou-Strauss, A., Enk, A., & Hassel, J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0083 · Cited by 58
Self-citationCombination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58
Precision Therapy of Head and Neck Squamous Cell Carcinoma
Polverini, P. J., D’Silva, N. J., & Lei, Y. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518769645 · Cited by 62
Shields, B. D., Koss, B. S., Taylor, E. M., Storey, A. J., West, K. L., Byrum, S. D., Mackintosh, S. G., Edmondson, R., Mahmoud, F. A., Shalin, S. C., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1722 · Cited by 68
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 62
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Shi, S., Gu, S. S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0778 · Cited by 60
“Multiple factors have been reported to affect ICB response and resistance, including cytotoxic T-cell infiltration (7), mutation load (8–10), antigen presentation (11–14), PD-L1 expression (15, 16), gut microbiome (17), interferon signaling (14, 18, 19), PI3K pathway (20, 21), and beta-catenin signaling (22).”
BackgroundDeep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
Sidhom, J.-W., Oliveira, G., Ross-MacDonald, P., Wind-Rotolo, M., Wu, C. J., Pardoll, D. M., & Baras, A. S. (2022) · Science Advances · doi:10.1126/sciadv.abq5089 · Cited by 57
Self-citationZhang, P., Pei, S., Wu, L., Xia, Z., Wang, Q., Huang, X., Li, Z., Xie, J., Du, M., & Lin, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1196372 · Cited by 60
“Additionally, we retrieved the Immunophenoscores (IPS) for LUAD from The Cancer Immunome Atlas (TCIA) database (29).”
MethodSprooten, J., Vanmeerbeek, I., Datsi, A., Govaerts, J., Naulaerts, S., Laureano, R. S., Borràs, D., Calvet, A., Malviya, V., Kuballa, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101377 · Cited by 75
Gandara, D. R., Agarwal, N., Gupta, S., Klempner, S. J., Andrews, M. C., Mahipal, A., Subbiah, V., Eskander, R. N., Carbone, D. P., Riess, J. W., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010311 · Cited by 76
Rajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong, Y. N. S., Joshi, K., Khetrapal, P., Ismail, M., Reading, J. L., Sunderland, M. W., Georgiou, A., Furness, A. J. S., Ben Aissa, A., Ghorani, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20181003 · Cited by 57
Melo, A. M., O’Brien, A., Phelan, J. J., Kennedy, S. A., Wood, N., Veerapen, N., Besra, G. S., Clarke, N. E., Foley, E. K., Ravi, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01580 · Cited by 63
“well to immune checkpoint inhibitor treatment (66, 67), yet results to date have been modest, with only a minority of patients benefitting from treatment (68, 69).”
BackgroundToward in silico Identification of Tumor Neoantigens in Immunotherapy
Zhou, C., Zhu, C., & Liu, Q. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.08.001 · Cited by 57
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Forrest, S. J., Al‐Ibraheemi, A., Doan, D., Ward, A., Clinton, C. M., Putra, J., Pinches, R. S., Kadoch, C., Chi, S. N., DuBois, S. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3089 · Cited by 58
“PD-L1 expression and responses to immune checkpoint blockade have also been seen in cancers harboring loss of SMARCA4, another subunit of the SWI/SNF complex, despite low TMB (44, 45).”
InfluentialHuemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 62
Palmieri, G., Colombino, M., Cossu, A., Marchetti, A., Botti, G., & Ascierto, P. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1119-6 · Cited by 48
“Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.”
BackgroundInfluentialHilke, F. J., Sinnberg, T. W., Gschwind, A., Niessner, H., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Bonzheim, I., Röcken, M., Rieß, O., et al. (2020) · Cancers · doi:10.3390/cancers12092359 · Cited by 73
“With regards to the differences between the melanoma subtypes [50,51] and the identification of potential druggable targets, this is probably not that relevant.”
BackgroundLong, J., Wang, D., Wang, A., Chen, P., Lin, Y. S., Bian, J., Yang, X., Zheng, M., Zhang, H., Zheng, Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01024-y · Cited by 63
ImmunoPET imaging of Trop2 in patients with solid tumours
Huang, W., Zhang, Y., Cao, M., Wu, Y., Jiao, F., Chu, Z., Zhou, X., Li, L., Xu, D., Pan, X., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00059-5 · Cited by 60
“…limitations caused by various factors, such as the deep anatomical location and the spatiotemporal heterogeneity of the tumour, leading to dif fi culties in invasive tissue collection and inaccurate evaluation of the heterogeneous tumours (Chen et al, 2016; Hegde et al, 2016; Van Allen et al, 2015).”
Community assessment of methods to deconvolve cellular composition from bulk gene expression
White, B. S., de Reyniès, A., Newman, A. M., Waterfall, J. J., Lamb, A. E., Petitprez, F., Lin, Y., Yu, R., Guerrero-Gimenez, M. E., Domanskyi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50618-0 · Cited by 73
Wang, J., Yi, Y., Xiao, Y., Lin, D., Liang, L., Teng, L., Ying, J. M., Lu, T., Liu, Y., Guan, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0212-1 · Cited by 62
Corley, S., Troy, N. M., Bosco, A., & Wilkins, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-55434-x · Cited by 66
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Re-Evaluating Clonal Dominance in Cancer Evolution
Burrell, R. A., & Swanton, C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.04.002 · Cited by 58
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.